ViroGates AS (FRA:EP2) Stock Based Compensation: €0.00 Mil (TTM As of Mar. 2026)


FRA:EP2 ViroGates AS FRA:EP2
44 GF Score
Price €1.45
GF Value €0.90
! 2 Warning Signs
View Full Analysis

What is ViroGates AS Stock Based Compensation?

ViroGates AS FRA:EP2 +2.84% 44 Stock Based Compensation is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:EP2 with a GF Score™ of 44/100 and a GF Value™ of €0.90. The stock has 2 warning signs investors should review.

ViroGates AS's Stock Based Compensation for the three months ended in Mar. 2026 was €0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

ViroGates AS Stock Based Compensation Related Terms

ViroGates AS Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for ViroGates AS's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ViroGates AS Stock Based Compensation Chart

ViroGates AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ViroGates AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:EP2
44GF Score
ViroGates AS FRA:EP2
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ViroGates AS Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

What does a Stock Based Compensation of €0.00 Mil mean?
ViroGates AS (FRA:EP2) has a Stock Based Compensation of €0.00 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for ViroGates AS and its competitors.
Is ViroGates AS's Stock Based Compensation too high?
ViroGates AS's current Stock Based Compensation is €0.00 Mil. Overall, ViroGates AS has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's Stock Based Compensation compare to ABT and SYK?
ViroGates AS's Stock Based Compensation of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for ViroGates AS and its competitors. ViroGates AS's current Stock Based Compensation is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
ViroGates AS (FRA:EP2) has a current Stock Based Compensation of €0.00 Mil. The stock's GF Value™ is €0.90, compared to a current price of €1.45 — trading 61.1% above its estimated fair value. The current Stock Based Compensation is €0.00 Mil. ViroGates AS's overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For ViroGates AS (FRA:EP2), the current Stock Based Compensation is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ViroGates AS (FRA:EP2) Overvalued in 2026?

Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued. The current stock price of €1.45 is trading 61.1% above its estimated GF Value™ of €0.90.

Key valuation signals for FRA:EP2:

  • Stock Based Compensation: €0.00 Mil
  • GF Value™: €0.90 vs. price of €1.45 (61.1% above fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the FRA:EP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ViroGates AS Business Description

Other Exchanges VIRO:Denmark
Address Banevaenget 13, Birkerod, DNK, 3460
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
44GF Score

Get the complete analysis for FRA:EP2

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.45
Price
€0.90
GF Value